Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTYX vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTYX Captures Overall Composite Edge (50.4 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars

VTYX Overall Winner 6-Pillar Tally: VTYX 2 – 3 FDMT (1 Tie) Matrix Metrics: VTYX 6 – 2 FDMT

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.4/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus FDMT at $11.41 (N/M Forward P/E, -222.7% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs FDMT
VTYX NASDAQ Head-to-Head Winner
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.41
-6.7% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.90β · 91% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (VTYX 2 – 3 FDMT)

Columns: Metric · VTYX · FDMT
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +0.0% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $96M
Market Cap $1.0B $669.3M
3. Profitability & Quality VTYX
Gross Margin N/A N/A
Operating Margin 0.0% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -45.4% -56.7%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) N/A -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 0.5% (<1st %ile) 82.4% (10th %ile)
Put/Call OI Skew N/A 5.16x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (6) vs FDMT (2)
Institutional Metric VTYX FDMT Criterion Row Edge
Market Capitalization
Scale
$1.0B $669.3M Larger Scale VTYX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
0.0% -222.7% Higher Margin VTYX
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin VTYX
Return on Equity (ROE)
Capital Efficiency
-45.4% -56.7% Higher ROE VTYX
52-Week Range Position
Momentum
55% ($1–$25) 45% ($7–$17) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 1.90β · 91% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
N/A $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +4.87 pp
VTYX: +0.36% · FDMT: -4.51%
3M Horizon VTYX +67.44 pp
VTYX: +40.0% · FDMT: -27.44%
6M Horizon VTYX +64.3 pp
VTYX: +46.6% · FDMT: -17.7%
1Y Horizon VTYX +64.3 pp
VTYX: +46.6% · FDMT: -17.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs FDMT. Trailing 12-month operating profitability (VTYX 0.0% vs FDMT -222.7%) and valuation multiples (VTYX N/M vs FDMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
FDMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$96M
Gross MarginN/A
Op. Margin-222.7%
ROE / Fwd P/E-56.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.4/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus FDMT at $11.41 (N/M Forward P/E, -222.7% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY). Technical & Structure Timing Caution: VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $96M for FDMT. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

FDMT screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.90β · 91% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.